Table 1.
On-Study Characteristics (n=115)
| n | (%) | |
|---|---|---|
| Gender | ||
| Male | 69 | (60%) |
| Female | 46 | (40%) |
| Race (n=110) | ||
| White | 110 | (100%) |
| Performance Status (n=113) | ||
| 0 | 74 | (65.5%) |
| 1 | 39 | (34.5%) |
| Depth of Invasion (n=80) | ||
| I | 1 | (1.3%) |
| II | 8 | (10.0%) |
| III | 22 | (27.5%) |
| IV | 32 | (40.0%) |
| V | 17 | (21.3%) |
| Primary Tumor Site (n=106) | ||
| Head and Neck | 19 | (17.9%) |
| Upper Limb | 5 | (4.7%) |
| Lower Limb | 17 | (16%) |
| Trunk | 46 | (43.4%) |
| Anagenital | 2 | (1.9%) |
| Ocular | 8 | (7.6%) |
| Mucosal | 4 | (3.8%) |
| Other | 5 | (4.7%) |
| Histologic Type (n=79) | ||
| Amelanotic | 6 | (7.6%) |
| Melanotic | 73 | (92.4%) |
| Sites of Distant Metastasis | ||
| (Visceral Involvement) | Measurable (n) | Non-measurable (n) |
| Lung | 70 | 11 |
| Pleura | 1 | 1 |
| Liver | 24 | 5 |
| Brain/CNS | 0 | 1 |
| Bone | 0 | 6 |
| Other Visceral | 18 | 6 |
| Sites of Distant Metastasis | ||
| (Non-visceral Involvement) | Measurable (n) | Non-measurable (n) |
| Distant nodes | 29 | 5 |
| Soft tissue | 23 | 6 |
| Skin | 19 | 2 |
| Other non-visceral | 12 | 4 |
| AJCC M Stage (n=111) | ||
| M1a | 20 | (18%) |
| M1b | 47 | (42.4%) |
| M1c | 44 | (39.6%) |
| Age (years) | ||
| Median | 62 | |
| Age (years) | 23 – 83 | |
| Breslow Thickness (mm) (n=81) | ||
| Median | 2.5 | |
| Range | 28 – 24 | |
| Prior Treatment | ||
| Surgery | 109 | |
| Chemotherapy | 24 | |
| Radiotherapy | 22 | |
| Immunotherapy | 44 | |
| Hormonal Therapy | 1 | |
| Gene Therapy | 1 | |
| Other | 9 |
*
Accrual by Institution > 5%
1). University of Pittsburgh, 23.3%; 2). University of Wisconsin, 10.00%; 3). Mayo Clinic Rochester, 10.0%;
4). University of Pennsylvania, 8.3%; 5). Johns Hopkins University, 7.5%; 6). Beth Israel Deaconess Medical Center, 6.7%;
7). Emory University, 6.7%.